SUMMARY PRODUCT INFORMATION 3 INDICATIONS AND CLINICAL USE 3 CONTRAINDICATIONS 4 WARNINGS AND PRECAUTIONS 4 ADVERSE REACTIONS 8 DRUG INTERACTIONS 15 DOSAGE AND ADMINISTRATION 18 OVERDOSAGE 19 ACTION AND CLINICAL PHARMACOLOGY 20 ACTION AND CLINICAL PHARMACOLOGY 22 STORAGE AND STABILITY 23 SPECIAL HANDLING INSTRUCTIONS 23 DOSAGE FORMS, COMPOSITION AND PACKAGING 23

PART II: SCIENTIFIC INFORMATION 24

PHARMACEUTICAL INFORMATION 24 CLINICAL TRIALS 24 DETAILED PHARMACOLOGY 25 TOXICOLOGY 28 REFERENCES 31

PART III: CONSUMER INFORMATION. 34

REMERON(r)

PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION

CONTRAINDICATIONS

Hypersensitivity: REMERON(r) is contraindicated in patients who are known to be hypersensitive to the drug or any of its components. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING. Monoamine Oxidase Inhibitors: In patients receiving agents that may affect the serotonergic neurotransmitter systems in combination with a monoamine oxidase (MAO) inhibitor, there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have begun treatment on a MAO inhibitor. Some cases presented with features resembling serotonin syndrome or neuroleptic malignant syndrome (see WARNINGS AND PRECAUTIONS - Neurologic - Serotonin Syndrome/Neuroleptic Malignant Syndrome). Therefore, REMERON(r) should not be used in combination with MAO inhibitors (including linezolid, an antibiotic which is a reversible non-selective MAO inhibitor) or within a minimum of 2 weeks of terminating treatment with MAO inhibitors. Treatment with REMERON(r) should then be initiated cautiously and dosage increased gradually until optimal response is reached. MAO inhibitors should not be introduced within 2 weeks of cessation of therapy with REMERON(r).

WARNINGS AND PRECAUTIONS

POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM

Pediatrics: Placebo-Controlled Clinical Trial Data

Recent analyses of placebo-controlled clinical trial safety databases from SSRIs (Selective Serotonin Reuptake Inhibitors) and other newer anti-depressants suggest that use of these drugs in patients under the age of 18 may be associated with behavioural and emotional changes, including an increased risk of suicidal ideation and behaviour over that of placebo.

The small denominators in the clinical trial database, as well as the variability in placebo rates, preclude reliable conclusions on the relative safety profiles among these drugs.

Adults and Pediatrics: Additional Data

There are clinical trial and post-marketing reports with SSRIs and other newer anti-depressants, in both pediatrics and adults, of severe agitation-type adverse events coupled with self-harm or harm to others. The agitation-type events include akathisia, agitation, disinhibition, emotional lability, hostility, aggression and depersonalization. In some cases, the events occurred within several weeks of starting treatment.

Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages. This includes monitoring for agitation- type emotional and behavioural changes.

Discontinuation Symptoms

Patients currently taking REMERON(r) should NOT discontinue treatment abruptly, due to risk of discontinuation symptoms. At the time that a medical decision is made to discontinue an SSRI or other newer anti-depressant drug, a gradual reduction in the dose, rather than an abrupt cessation, is recommended.

Lactose

Lactose is a non-medicinal ingredient in REMERON(r) tablets. Therefore, patients with rare hereditary problems of galactose intolerance or glucose-galactose malabsorption should not take REMERON(r) tablets.

Agranulocytosis

In pre-marketing clinical trials, two (one with Sjogren's Syndrome) out of 2,796 patients treated with REMERON(r) (mirtazapine) Tablets and one patient treated with imipramine developed agranulocytosis. In all three cases, the patients recovered after the drug with which they were being treated was stopped. In the post-marketing period with REMERON(r), very rare cases of agranulocytosis have been reported, mostly reversible, but in some cases fatal. All fatal cases concerned patients with an age above 65. If a patient develops a sore throat, fever, stomatitis or other signs of infection, along with a low WBC count, treatment with REMERON(r) should be discontinued and the patient should be closely monitored.

Discontinuation of Treatment with REMERON(r)

When discontinuing treatment, patients should be monitored for symptoms which may be associated with discontinuation, e.g., dizziness, abnormal dreams, sensory disturbances (including paresthesia and electric shock sensations), agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting and sweating or other symptoms which may be of clinical significance (see ADVERSE REACTIONS). A gradual reduction in the dosage over several weeks, rather than abrupt cessation, is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient's clinical response (see ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION). The following additional precautions are listed alphabetically.

Cholesterol/Triglycerides: In U.S. short-term controlled studies, non-fasting cholesterol increases of > 20% above the upper limits of normal were observed in 15% of patients taking REMERON(r) compared to 7% for placebo. In these same studies, non-fasting triglycerides increased to > 500 mg/dl in 6% of patients taking REMERON(r) compared to 3% for placebo.

Use in Patients with Concomitant Illness: Clinical experience with REMERON(r) in patients with concomitant systemic illness is limited. Accordingly, care is advisable in prescribing REMERON(r) for patients with diseases or conditions that affect metabolism or hemodynamic

responses. REMERON(r) has not been systematically evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or other significant heart disease. REMERON(r) was associated with significant orthostatic hypotension in early clinical pharmacology trials with normal human volunteers. Orthostatic hypotension was infrequently observed in clinical trials with depressed patients. REMERON(r) should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication).

Physical and Psychological Dependence: REMERON(r) (mirtazapine) has not been systematically studied in animals or humans for its potential for abuse, tolerance or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking behaviour, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted and/or abused once marketed. Consequently, patients should be evaluated carefully for history of drug abuse, and such patients should be observed closely for signs of REMERON(r) misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behaviour).

Increased Appetite/Weight Gain: In U.S. short-term controlled studies, the use of REMERON(r) was associated with increased appetite in 17% and the complaint of weight gain in 12 % of patients, compared to 2% for placebo in both cases. In these same trials, weight gain of >= 7% occurred in 7.5% of the patients taking REMERON(r) compared to 0% in patients taking placebo. The average weight gain in the U.S. long-term controlled trials was 8 lb over 28 weeks.

Diabetes

Care should be taken in patients with micturition disturbances like prostate hypertrophy.

Hepatic Impairment

: Increased plasma concentrations of mirtazapine occur in patients with moderate and severe hepatic impairment (see ACTION AND CLINICAL PHARMACOLOGY- Special Populations and Conditions). In such patients, upward dose titration should be carefully monitored (see DOSAGE AND ADMINISTRATION).

Transaminase Elevations: In U.S. short-term controlled studies, clinically significant ALT (SGPT) elevations (3 times the normal range) were noted in 2%, respectively, of patients treated with REMERON(r) and in 0% of patients treated with placebo. Most patients did not develop signs or symptoms associated with compromised liver function. While some patients were discontinued due to ALT increases, other patients with elevations continued with enzyme levels returning to normal during ongoing treatment. Mirtazapine should be used with caution in patients with impaired hepatic function (see DOSAGE AND ADMINISTRATION).

Jaundice:

Somnolence: The use of REMERON(r) (mirtazapine) Tablets was associated with somnolence in 54% of patients in U.S. short-term controlled studies, compared to 18% with placebo. In these studies, somnolence resulted in discontinuation of 10% of mirtazapine-treated patients compared to 2% of placebo-treated patients. REMERON(r) may cause mental or motor impairment because of this prominent sedative effect. Thus, patients should be cautioned about engaging in hazardous activities, such as driving a car or operating dangerous machines, until they are reasonably certain that REMERON(r) therapy does not adversely affect their ability to engage in such activities. Dizziness: In U.S. short-term controlled studies, the use of REMERON(r) was associated with dizziness in 7% of patients, compared to 3% for placebo. Activation of Mania/Hypomania: Mania/hypomania occurred in approximately 0.2% (3/1,299 patients) of REMERON(r)-treated patients in all U.S. studies (controlled and non-controlled). Although the incidence of mania/hypomania was very low during treatment with REMERON(r), it should be used carefully in patients with a history of mania/hypomania. Seizures: In pre-marketing clinical trials, only one seizure was reported in the 2,796 U.S. and non-U.S. patients treated with REMERON(r). However, no controlled studies have been carried out in patients with a history of seizures. Therefore, care should be exercised when REMERON(r) is used in these patients. Serotonin Syndrome/Neuroleptic Malignant Syndrome: On rare occasions serotonin syndrome or neuroleptic malignant syndrome-like events have occurred in association with treatment of REMERON(r), particularly when given in combination with other serotonergic and/or neuroleptic/antipsychotic drugs. As these syndromes may result in potentially life- threatening conditions, treatment with REMERON(r) should be discontinued if patients develop a combination of symptoms possibly including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma and supportive symptomatic treatment should be initiated. Due to the risk of serotonergic syndrome or neuroleptic malignant syndrome REMERON(r) should not be used in combination with MAO inhibitors or serotonin-precursors (such as L-tryptophan, oxitriptan) and should be used with caution in patients receiving other serotonergic drugs (triptans, lithium, tramadol, St. John's Wort, most tricyclic antidepressants) or neuroleptics/antipsychotics (see CONTRAINDICATIONS and DRUG INTERACTIONS).

Care should be taken in patients with acute narrow-angle glaucoma and increased intra-ocular pressure.

Suicide: Suicidal ideation is inherent in depression and may persist until significant remission occurs. As with any patient receiving anti-depressants, high-risk patients should be closely supervised during initial drug therapy. Prescriptions of REMERON(r) should be written for the smallest quantity consistent with good patient management, in order to reduce the risk of

overdose (see WARNINGS AND PRECAUTIONS- General: POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM).

Renal and Hepatic Impairment

: Increased plasma concentrations of mirtazapine occur in patients with moderate and severe renal impairment and, to a lesser extent, in patients with hepatic impairment (see ACTION AND CLINICAL PHARMACOLOGY -Special Populations and Conditions). In such patients, upward dose titration should be carefully monitored (see DOSAGE AND ADMINISTRATION).

Pregnant Women: Safe use of REMERON(r) during pregnancy has not been established. Therefore, it should not be administered to women of childbearing potential or nursing mothers unless, in the opinion of the treating physician, the expected benefits to the patient outweigh the possible hazards to the child or fetus. Post-marketing reports indicate that some neonates exposed to SSRIs or other newer anti-depressants, such as REMERON(r), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability and constant crying. The frequency of symptoms may vary with each drug. These features are consistent with either a direct toxic effect of SSRIs and other newer anti-depressants, or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see WARNINGS AND PRECAUTIONS - Neurologic - Serotonin Syndrome/Neuroleptic Malignant Syndrome). When treating a pregnant woman with REMERON(r) during the third trimester, the physician should carefully consider the potential risks and benefits of treatment (see DOSAGE AND ADMINISTRATION). The extent of exposure in pregnancy during clinical trials: None. Nursing Women: Safe use of REMERON(r) during lactation has not been established.

Pediatrics (< 18 years of age):

Safety and effectiveness in children under 18 years of age have not been established.

Geriatrics (> 65 years of age)

: Pharmacokinetic studies revealed a decreased clearance in the elderly, especially in elderly females. Elderly patients may be more susceptible to adverse events such as sedation, dizziness or confusion. Care should be exercised in dosage and titration to higher doses (see ACTION AND CLINICAL PHARMACOLOGY; DOSAGE AND ADMINISTRATION; WARNINGSAND PRECAUTIONS - Neurologic - Somnolence).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Adverse Events Leading to Discontinuation of Treatment

Sixteen percent of patients treated with REMERON(r) (mirtazapine) Tablets in U.S. short-term controlled studies discontinued treatment due to an adverse event, compared to 7% of patients

REMERON(r) Tablets Page 8 of 37

treated with placebo. The adverse event that accounted for more than 5% of discontinuations with REMERON(r) was somnolence (10%). Commonly Observed Adverse Events in U.S. Short-Term Controlled Clinical Trials: The most commonly observed adverse events related to the use of REMERON(r) Tablets (5% or greater drug-related incidence for REMERON(r) Tablets and at least twice that of placebo) were somnolence (54% vs. 18%), increased appetite (17% vs. 2%), weight gain (12% vs. 2%) and dizziness (7% vs. 3%).

Clinical Trial Adverse Drug Reactions

Adverse Events Occurring at an Incidence of 1% or More Among REMERON(r)-Treated Patients:

The table that follows enumerates adverse events that occurred at an incidence of 1%

or more among REMERON(r)-treated patients (and greater than the incidence in placebo-treated patients) who participated in U.S. short-term placebo-controlled trials, in which patients were dosed in a range of 5 to 60 mg/day. The investigators reported adverse clinical experiences using terms of their own choice. Reported adverse events were then classified using the standard COSTART-based dictionary terminology. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other investigations involving different treatments, uses and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the side effect incidence rate in the population studied.

REMERON(r) Tablets Page 9 of 37

TABLE 1 INCIDENCE OF ADVERSE CLINICAL EXPERIENCES (>=1% for REMERON(r)) IN U.S. SHORT-TERM PLACEBO-CONTROLLED STUDIES1,2,3

Body System Adverse Event	REMERON (r) N = 453	Placebo N = 361
Body as a Whole
Asthenia	34 (8%)	17 (5%)
Flu Syndrome	22 (5%)	9 (3%)
Back Pain	9 (2%)	3 (1%)
Digestive System
Dry Mouth	112 (25%)	54 (15%)
Increased Appetite	76 (17%)	7 (2%)
Constipation	57 (13%)	24 (7%)
Metabolic and Nutritional Disorders
Weight Gain	54 (12%)	6 (2%)
Peripheral Edema	11 (2%)	4 (1%)
Edema	6 (1%)	1 (0%)
Musculoskeletal System
Myalgia	9 (2%)	3 (1%)
Nervous System
Somnolence	243 (54%)	65 (18%)
Dizziness	33 (7%)	12 (3%)
Abnormal Dreams	19 (4%)	5 (1%)
Thinking Abnormal	15 (3%)	4 (1%)
Tremor	7 (2%)	2 (1%)
Confusion	9 (2%)	1 (0%)
Respiratory System
Dyspnea	5 (1%)	1 (0%)
Urogenital System
Urinary Frequency	8 (2%)	5 (1%)

N= Number of Patients

% rounded off to the nearest whole integer.
Events which had an incidence on placebo > REMERON(r): infection, pain, headache, nausea, diarrhea and insomnia.
Events which had an incidence of REMERON(r) comparable to placebo: chest pain, palpitation, tachycardia, postural hypotension, dyspepsia, flatulence, libido decreased, hypertonia, nervousness, rhinitis, pharyngitis, sweating, amblyopia, tinnitus and taste

perversion.

REMERON(r) Tablets Page 10 of 37

There was evidence of adaptation to some adverse events with continued therapy (e.g., increased appetite, dizziness and somnolence). ECG Changes: The electrocardiograms for 338 patients who received REMERON(r) and 261 patients who received placebo in the U.S. short-term controlled trials were analyzed, in which the QTc calculations using the method of Fridericia was employed . Prolongation in QTc >= 500 msec was not observed among mirtazapine-treated patients. Mean change in QTc was +1.6 msec for mirtazapine and -3.1 msec for placebo. Mirtazapine was associated with a mean increase in heart rate of 3.4 bpm, compared to 0.8 bpm for placebo. The clinical significance of these changes is unknown.

Less Common Clinical Trial Adverse Drug Reactions (<1%)

During worldwide controlled and uncontrolled clinical trials, REMERON(r) was administered to 2,796 patients. The listing of events which follows includes those events which were judged by the investigator to be adverse clinical experiences. The investigators used terminology of their own choice to describe the adverse experiences. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized categories. It is important to emphasize that although the events occurred during treatment with REMERON(r), they were not necessarily drug-related. Following the adverse experiences tabulations, the incidence of clinically significant laboratory values which occurred at a rate of >= 1% of patients is presented. In the tabulations that follow, adverse events as reported by the investigator were classified using a standard COSTART-based dictionary terminology. Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients, infrequent adverse events are those occurring in 1/100 to 1/1,000 patients, and rare events are those occurring in fewer than 1/1,000 patients. Only those events not already listed in Table 1 appear in this listing. Events of major clinical importance are also described in the WARNINGS AND PRECAUTIONS section.

Body as a Whole: frequent: infrequent: rare:

malaise, abdominal pain, abdominal syndrome acute;

chills, fever, face edema, ulcer, photosensitivity reaction, neck rigidity, neck pain, abdomen enlarged;

cellulitis, substernal chest pain.

Cardiovascular System: frequent: infrequent: rare:

hypertension, vasodilatation;

angina pectoris, myocardial infarction, bradycardia, ventricular extrasystoles, syncope, migraine, hypotension;

atrial arrhythmia, bigeminy, vascular headache, pulmonary embolus, cerebral ischemia, cardiomegaly, phlebitis, left heart failure.

Digestive System: frequent: infrequent: rare:

vomiting, anorexia;

eructation, glossitis, cholecystitis, nausea and vomiting, gum hemorrhage, stomatitis, colitis, liver function tests abnormal;

tongue discolouration, ulcerative stomatitis, salivary gland enlargement, increased salivation, intestinal obstruction, pancreatitis, aphthous stomatitis, cirrhosis of liver, gastritis, gastroenteritis, oral moniliasis, tongue edema.

REMERON(r) Tablets Page 11 of 37

Endocrine System: rare:

goiter, hypothyroidism.

Hemic and Lymphatic Systems: rare:

lymphadenopathy, leukopenia, petechia, anemia, thrombocytopenia, lymphocytosis, pancytopenia.

Metabolic and Nutritional Disorders: frequent: infrequent: rare:

thirst;

dehydration, weight loss,

gout, SGOT increased, healing abnormal, acid phosphatase increased, SGPT increased, diabetes mellitus.

Musculoskeletal System: frequent: infrequent: rare:

myasthenia, arthralgia;

arthritis, tenosynovitis;

pathologic fracture, osteoporosis fracture, bone pain, myositis, tendon rupture, arthosis, bursitis.

Nervous System: frequent: infrequent: rare:

hypoesthesia, apathy, depression, hypokinesia, vertigo, twitching, agitation, anxiety, amnesia, hyperkinesia, paresthesia;

ataxia, delirium, delusions, depersonalization, dyskinesia, extrapyramidial syndrome, libido increased, coordination abnormal, dysarthria, hallucinations, manic reaction, neurosis, dystonia, hostility, reflexes increased, emotional lability, euphoria, paranoid reaction;

aphasia, nystagmus, akathisia, stupor, dementia, diplopia, drug dependence, paralysis, grand mal convulsion, hypotonia, myoclonus, psychotic depression, withdrawal syndrome.

Respiratory Systems: frequent: infrequent: rare:

cough increased, sinusitis;

epistaxis, bronchitis, asthma, pneumonia;

asphyxia, laryngitis, pneumothorax, hiccup.

Skin and Appendages: frequent: infrequent: rare:

pruritus, rash;

acne, exfoliative dermatitis, dry skin, herpes simplex, alopecia;

urticaria, herpes zoster, skin hypertrophy, seborrhea, skin ulcer.

Special Senses: infrequent: rare:

eye pain, abnormality of accommodation, conjunctivitis, deafness, keratoconjunctivitis, lacrimation disorder, glaucoma, hyperacusis, ear pain;

blepharitis, partial transitory deafness, otitis media, taste loss, parosmia.

Urogenital System: frequent: infrequent: rare:

urinary tract infection;

kidney calculus, cystitis, dysuria, urinary incontinence, urinary retention, vaginitis, hematuria, breast pain, amenorrhea, dysmenorrhea, leukorrhea, impotence,

polyuria, urethritis, metrorrhagia, menorrhagia, abnormal ejaculation, breast engorgement, breast enlargement, urinary urgency.

Abnormal Hematologic and Clinical Chemistry Findings

Abnormal Laboratory Values:

Elevated cholesterol, serum glucose and triglycerides were the most common blood chemistry parameters observed in U.S. studies.

The plasma samples were drawn from non-fasting patients, and these parameters are affected by diet. Patients taking REMERON(r) had increased appetite and weight gain, and are likely to have had increased food intake. Increased food intake may account for the increased triglyceride and cholesterol values. Moreover, LDL:HDL ratio data from a limited number of patients suggest that fat metabolism does not change with REMERON(r) treatment, further suggesting that the increase in triglyceride and cholesterol values reflected increased dietary intake. Mild changes in liver function are shown by increases in liver enzymes. However, changes are temporary, mild, and are not expected to negatively influence liver function. Premature

REMERON(r) Tablets Page 12 of 37

terminations due to liver enzyme abnormalities were, respectively, REMERON(r), 1.7% and placebo, 1.1%. The incidence of neutropenias in all clinical studies for REMERON(r) was 1.5%. Most of the observed cases of neutropenia were mild isolated and nonprogressive (see WARNINGS AND PRECAUTIONS).

Post-Market Adverse Drug Reactions

Adverse Events Observed During Post-Marketing Evaluation of REMERON(r)

Adverse events reported since market introduction, which were temporally (but not necessary causally) related to mirtazapine therapy, include four cases of the ventricular arrhythmia torsades de pointes. In three of the four cases, however, concomitant drugs were implicated. All patients recovered. Other adverse events observed post-marketing listed by System Organ Class and by frequency are found in table 2.

REMERON(r) Tablets Page 13 of 37

Table 2. Post-marketing reported adverse events with REMERON(r)

System organ class	Very common (>=1/10)	Common (>1/100 to <1/10)	Uncommon (>1/1,000 to <= 1/100)	Rare (>1/10,000 to <= 1/1,000)	Very rare ( <= 1/10,000)
Blood and the lymphatic system disorders				Bone marrow Eosinophilia depression (granulocytopenia, agranulocytosis, aplastic anemia and thrombocytopenia) (see also WARNINGS AND PRECAUTIONS, Agranulocytosis)
Metabolism and nutrition disorders		- Increase in appetite
Psychiatric disorders				Nightmares/vivid Mania Agitation Confusion Hallucinations Anxiety * Insomnia * Psychomotor restlessness * * dreams
Nervous system disorders		Somnolence (which Headache can lead to impaired concentration), generally occurring during the first few weeks of treatment. (N.B. : Dose reduction generally does not lead to less sedation but can jeopardize anti- depressant efficacy). -Dizziness		Convulsions Paraesthesia Restless legs (insults), tremor, myoclonus -Syncope	Oral paraesthesia Serotonin syndrome
Vascular disorders				- (Orthostatic) hypotension
Gastrointestinal disorders			Nausea	Dry mouth Diarrhea	Oral hypoesthesia Mouth edema
Hepato-biliary disorders				- Elevations in serum transaminase activities
Skin and subcutaneous tissue disorders				- Exanthema
Musculoskeletal, connective tissue and bone disorders				- Arthralgia/myalgia
General disorders and administration site conditions		- Generalised or local edema		- Fatigue
Investigations		- Weight gain

Upon treatment with anti-depressants in general, anxiety and insomnia (which may be symptoms of depression) can develop or become aggravated. Under REMERON(r) treatment, development or aggravation of anxiety and insomnia has been reported very rarely.

* * Incl. akathisia, hyperkinesia

REMERON(r) Tablets Page 14 of 37

Adverse Reactions following Discontinuation of Treatment (or Dose Reduction)

There have been reports of adverse reactions upon the discontinuation of REMERON(r) (particularly when abrupt), including but not limited to the following: dizziness, abnormal dreams, sensory disturbances (including paraesthesia and electric shock sensations), agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting and sweating or other symptoms which may be of clinical significance (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION). Patients should be monitored for these or any other symptoms. A gradual reduction in the dosage over several weeks, rather than abrupt cessation, is recommended whenever possible. If intolerable symptoms occur following a decrease in dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient's clinical response. These events are generally self-limiting. Symptoms associated with discontinuation have been reported for other anti-depressants with serotonergic effects (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

DRUG INTERACTIONS

Serious Drug Interactions

Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS

As with other drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.) is a possibility (see CLINICAL PHARMACOLOGY). The metabolism and pharmacokinetics of mirtazapine may be affected by the induction or inhibition of drug-metabolizing enzymes. Mirtazapine is extensively metabolized by CYP2D6, CYP3A4, and to a lesser extent by CYP1A2.

Monoamine Oxidase Inhibitors: Combined use of REMERON(r) and monoamine oxidase inhibitors (including linezolid, an antibiotic which is a reversible non-selective MAO inhibitor) is contraindicated due to the potential for serious reactions with features resembling serotonin syndrome or neuroleptic malignant syndrome (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS - Neurologic Serotonin Syndrome/Neuroleptic Malignant Syndrome). Diazepam: The impairment of motor skills produced by REMERON(r) has been shown to be additive with those caused by diazepam. Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON(r).

CYP Enzyme Inducers

CYP3A4 Inducers (these studies used both drugs at steady state):

Phenytoin:

In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance, resulting in about a twofold decrease in plasma mirtazapine concentrations. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin. During combined use of mirtazapine and phenytoin, 3 out of 19 patients experienced fatigue and 1 out of 19 patients developed rash (and none had experienced either fatigue or rash with mirtazapine alone or phenytoin alone). The rash was severe enough to necessitate withdrawal from the study.

Carbamazepine:

In healthy male patients (n=24), carbamazepine (400 mg b.i.d.) increased mirtazapine (15 mg b.i.d.) clearance, resulting in about a twofold decrease in plasma mirtazapine concentrations.

When phenytoin, carbamazepine or another inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased. If treatment with such a medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.

CYP Enzyme Inhibitors

Cimetidine:

In healthy male patients (n=12), when cimetidine (800 mg b.i.d.) at steady state was co-administered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased by about 60%. Mirtazapine did not significantly change the pharmacokinetics of cimetidine. During combined use, side effects included somnolence [10 of 12 patients (including 1 of moderate severity) vs. 7 of 12 with mirtazapine alone and none with cimetidine alone], arrhythmia (2 of 12 patients vs. none with mirtazapine or cimetidine alone). The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.

Ketoconazole:

In healthy, male, Caucasian patients (n=24), co-administration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30 mg dose mirtazapine by approximately 40% and 50% respectively. During combined use, 2 severe adverse events have been reported: One patient experienced circulatory collapse and another patient experienced syncope. Both patients have lost consciousness for a brief period. Caution should be exercised when co-administering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin or nefazodone.

Paroxetine: In an in vivo interaction study in healthy, CYP2D6 extensive metabolizer patients (n=24), mirtazapine (30 mg/day), at steady state, did not significantly change the pharmacokinetics of steady state paroxetine (40mg/day), a CYP2D6 inhibitor. However, plasma concentrations of mirtazapine and its demethyl metabolite were slightly higher (about 18 and 25%, respectively) during combined administration with paroxetine. This difference is considered to be without clinical relevance. During combined use, side effects included exanthema (1 of 24 patients) that required withdrawal of the patient. Increases in AST and ALT were also reported, with a greater increase in men due to several outliers (including a patient that was withdrawn due to high AST (about 4 fold higher than the upper normal limit) and ALT (about 2 fold higher than the upper normal limit) levels; this patient also showed elevated WBC, neutrophils, decreased lymphocytes and basophils). AST/ALT levels returned to normal following the end of the treatment. Caution is advised for the co-administration of paroxetine with mirtazapine.

Other Drug-Drug Interactions

Amitriptyline

: In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not change the pharmacokinetics of steady state mirtazapine (30 mg daily) considerably and mirtazapine also did not change the pharmacokinetics of amitriptyline considerably. During combined use the following adverse reactions have been reported at considerably higher frequencies than with either drug alone: postural hypotension, impaired concentration (about 5 fold higher incidence), nausea (over 4 fold higher incidence) and dizziness (about 2 fold higher incidence). A CYP2D6 slow metabolizer patient experienced a serious adverse event following combined use of amitriptyline and mirtazapine. The subject complained of abdominal discomfort accompanied by dizziness and nausea and then leading to loss of consciousness for about 30 s. Apart from slight tremor (resembling myoclonic contractions) there were no other abnormalities. Caution is advised for the co-administration of amitriptyline with mirtazapine.

Warfarin:

In healthy male subjects (n=16) mirtazapine (30 mg daily), at steady state, caused a small (0.2) but statistically significant increase in the International Normalised Ratio (INR) in subjects treated with warfarin to achieve subtherapeutic levels of prothrombin activity (1.5-2.0 INR) at steady state. As at a higher dose of mirtazapine, a more pronounced effect can not be excluded it is advisable to monitor the INR in case of concomitant treatment of warfarin with mirtazapine.

Lithium:

No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of lithium (600 mg/day for 10 days) at steady state and a single 30 mg dose of mirtazapine. The serum levels of lithium were approximately 0.3 mmol/L 10 hrs after dosing. The effects of higher doses of lithium on the pharmacokinetics of mirtazapine are unknown.

Risperidone: In an in vivo non-randomized, interaction study subjects (n=6) in need of treatment with an antipsychiatric and antidepressant drug, the results of the effect of mirtazapine (30 mg daily) at steady state on the pharmacokinetics of risperidone (up to 3 mg b.i.d.) at steady state is inconclusive, due to high inter-patient variability and low number of patients. The study design does not permit conclusions to be made on the safety on the combined use of mirtazapine and risperidone. However, a case report of a male patient receiving combined treatment with mirtazapine (60 mg daily) and risperidone (3 mg daily) documents that, 6 weeks after initiation of this combination therapy, the patient developed pulmonary embolism and rhabdomyolysis. Caution is advised for the co-administration of risperidone with mirtazapine.

Serotonergic Drugs: Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when REMERON(r) is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, serotonin reuptake inhibitors, lithium, tramadol or St. John's Wort (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS - Neurologic - Serotonin Syndrome/Neuroleptic Malignant Syndrome). Drugs Bound to Plasma Protein: Because mirtazapine is bound to plasma proteins (85%), care should be exercised when REMERON(r) is co-administered to a patient who may be receiving another drug which is highly protein-bound.

St. John's Wort: Pharmacodynamic interactions between REMERON(r) and the herbal remedy St. John's Wort may occur and may result in an increase in undesirable effects. Dose adjustment of REMERON(r) should be considered if clinically indicated.

Alcohol: The impairment of mental and motor skills produced by REMERON(r) have been shown to be additive with those produced by alcohol. Accordingly, patients should be advised to avoid alcohol while taking REMERON(r).

DOSAGE AND ADMINISTRATION

REMERON(r) (mirtazapine) is not indicated for use in children under 18 years of age (see WARNINGS AND PRECAUTIONS: POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM)

TREATMENT OF PREGNANT WOMEN DURING THE THIRD TRIMESTER:

Post-marketing reports indicate that some neonates exposed to SSRIs or other newer anti-depressants, such as REMERON(r), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support and tube feeding (see WARNINGS AND PRECAUTIONS). When treating pregnant women with REMERON(r) during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering REMERON(r) in the third trimester.

Children:

See WARNINGS AND PRECAUTIONS: POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM

ELDERLY AND PATIENTS WITH MODERATE TO SEVERE RENAL OR HEPATIC

IMPAIRMENT: In elderly patients, and patients with moderate to severe renal or hepatic impairment, limited pharmacokinetic data (see ACTION AND CLINICAL PHARMACOLOGY) demonstrates increased serum concentration and/or reduced clearance of REMERON(r). REMERON(r) should thus be dosed with care in these populations (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).

ADULTS:

REMERON(r) (mirtazapine) Tablets should be administered as a single dose, preferably in the evening prior to sleep. The recommended initial dose is 15 mg daily. In clinical trials, patients generally received doses of REMERON(r) in the range of 15 - 45 mg/day. While a relationship between dose and anti-depressant response for REMERON(r) has not been established, patients not responding to the initial 15 mg dose may benefit from dose increases up to a maximum of 45 mg/day (see ACTION AND CLINICAL PHARMACOLOGY, Clinical Trials Showing Efficacy). REMERON(r) has an elimination half-life of approximately 20 - 40 hours, therefore, dose changes should occur in intervals of not less than one week. Dosage adjustments may be made according to the tolerance and based on the patient's response.

It is generally agreed that acute episodes of depression require several months or longer of sustained therapy beyond response to the acute episode. Systematic evaluation of REMERON(r) has demonstrated that its efficacy in major depressive disorder is maintained for periods of up to 40 weeks following 8 - 12 weeks of initial treatment at a dose 15 - 45 mg/day (see ACTION AND CLINICAL PHARMACOLOGY). Based on these limited data, it is unknown whether or not the dose of REMERON(r) needed for continuation treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassessed to determine the need for continuation treatment and the appropriate dose for such treatment.

Symptoms associated with the discontinuation or dose reduction of REMERON(r) have been reported. Patients should be monitored for these and other symptoms when discontinuing treatment or during dosage reduction (see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS). A gradual reduction in the dose over several weeks, rather than abrupt cessation, is recommended whenever is possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, dose titration should be managed on the basis of the patient's clinical response (see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS).

Do not take a double dose to make up for forgotten doses. If a patient forgets to take the evening dose, advise the patient not to take the missed dose the next morning. Continue treatment in the evening (prior to sleep) with the normal dose.

Administration of REMERON(r) (Mirtazapine) Tablets

Patients should be instructed to take the tablets at the same time each day, preferably as a single evening dose (prior to sleep). The tablets should be swallowed whole with water. The patient should be instructed not to chew the tablet (see PART III - Information for the Patient).

OVERDOSAGE

Human Experience: In clinical trials, the only drug overdose death reported while taking REMERON(r) (mirtazapine) Tablets was in combination with amitriptyline and chlorprohixene in a non-U.S. clinical study. Based on plasma levels, the REMERON(r) dose taken was 30 - 45 mg, while plasma levels of amitriptyline and chlorprohixene were found to be at toxic levels. In other pre-marketing overdose cases with REMERON(r) Tablets, the following signs and symptoms were reported: disorientation, drowsiness, impaired memory and tachycardia. There were no reports of ECG abnormalities, coma or convulsions following overdose with REMERON(r) Tablets alone. In post-marketing experience with more than 35 million patients exposed to REMERON(r) (based on average treatment courses of 30 mg/day during 3 months), fatal cases of overdose with

REMERON(r) alone have been reported. In many cases details regarding the precise dose are lacking. Fatal acute overdoses with REMERON7 alone are documented at doses as low as approximately 440 mg, which is estimated from the post-mortem plasma levels, assuming linear pharmacokinetics. However, survival has also been reported with a single REMERON(r) overdose as high as 1350 mg. Present experience concerning overdose with REMERON(r) alone indicates that symptoms are usually mild. Depression of the central nervous system with disorientation and prolonged sedation has been reported, together with tachycardia and mild hyper- or hypotension. However, there is a possibility of more serious outcomes (including fatalities) at dosages much higher than the therapeutic dose, especially with mixed overdosages.

Overdose Management:

Treatment should consist of those general measures employed in the management of overdose with any anti-depressant.

Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. There is no experience with the use of forced diuresis, dialysis, hemoperfusion or exchange transfusion in the treatment of mirtazapine overdosage. No specific antidotes for mirtazapine are known. In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control centre for additional information on the treatment of any overdose.

ACTION AND CLINICAL PHARMACOLOGY

The mechanism of action of REMERON(r) (mirtazapine) Tablets, as with other drugs effective in the treatment of major depressive disorder, is unknown. Evidence gathered in preclinical studies suggests that mirtazapine enhances central noradrenergic and serotonergic activity. These studies have shown that mirtazapine acts as an antagonist at central presynaptic a2 adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. The clinical relevance of this finding is unknown.

REMERON(r) acts as an antagonist at central presynaptic a2 adrenergic inhibitory autoreceptors and heteroreceptors, which results in an increase in central noradrenergic and serotonergic activity. The clinical relevance of this finding is unknown, however, this action may explain its anti-depressant activity. REMERON(r) is a potent antagonist of 5-HT2 and 5-HT3 receptors. The clinical relevance of this finding is unclear, however, the 5-HT2 and 5-HT3 antagonism by REMERON(r) may account for

its low rate of nausea, insomnia and anxiety as observed in clinical trials. REMERON(r) has no significant direct effect on 5-HT1A and 5-HT1B receptors. Both enantiomers of REMERON(r) appear to contribute to its pharmacological activity. The (+)enantiomer blocks 5-HT2 receptors as well as a2 receptors, and the (-)enantiomer blocks 5- HT3 receptors. The clinical relevance of this finding is unclear, but this may explain its anti- depressant activity and side-effects profile. REMERON(r) is a potent histamine (H1) receptor antagonist, which may contribute to its sedative effect and possibly to weight gain due to increased appetite. REMERON(r) is a moderate peripheral a1 adrenergic antagonist, a property which may explain the occasional orthostatic hypotension reported in association with its use. REMERON(r) is a moderate antagonist at muscarinic receptors, a property that may explain the occasional occurrence of anticholinergic side effects associated with its use as shown in clinical trials.

REMERON(r) is well absorbed following oral administration and its absolute bioavailability is approximately 50% after either single or multiple doses. Peak plasma concentrations are reached within about 2 hours following an oral dose. The time to peak plasma concentration is independent of dose. The presence of food in the stomach somewhat slows the rate but not the extent of absorption, and thus does not require a dosage adjustment. Plasma levels are linear over a dose range of 30 to 80 mg. Steady-state plasma levels are attained within about 5 days. The half-life of elimination of REMERON(r) after oral administration is approximately 20 - 40 hours. Metabolism: REMERON(r) is extensively metabolized and quantitatively eliminated via urine (75%) and feces (15%); approximately 90% of this elimination occurs within the first 72 - 96 hours. Major pathways of biotransformation are demethylation and oxidation followed by conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-demethyl and N-oxide metabolite. The demethyl metabolite is pharmacologically active and appears to have a similar pharmacokinetic profile as that of the parent compound. The (-)enantiomer has an elimination half-life that is approximately twice as long, and achieves plasma levels that are three times as high as that of the (+)enantiomer. Protein Binding: REMERON(r) is approximately 85% bound to plasma proteins over a concentration range of 10 to 1,000 ng/mL. Binding appears to be both non-specific and reversible. The binding affinity of mirtazapine to human liver proteins is 2.8 times greater than to human plasma proteins. As with all drugs that are protein-bound, care should be exercised when co-administering medications that may interact with REMERON(r) at protein-binding sites (see WARNINGS AND PRECAUTIONS).

TABLE 3 EFFECT OF AGE AND GENDER ON PLASMA HALF-LIFE OF MIRTAZAPINE

Pediatrics: REMERON(r) is not indicated for use in patients below the age of 18 years (see WARNINGS AND PRECAUTIONS- GENERAL- POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM; and DOSAGE AND ADMINISTRATION).

Geriatrics:

Following administration of REMERON(r) 20 mg/day for 7 days, oral clearance was reduced in older subjects (mean age 65; range 55- 75) compared to younger subjects (see Table 3). The difference was greatest in males, with a 40% lower clearance for REMERON(r) in the older vs. younger group. Caution is indicated in administering REMERON(r) (mirtazapine) Tablets in the elderly (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Gender:

Age and Sex:

In the same study above (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics) females of all ages (range 25 - 74) exhibited significantly longer elimination half-lives than males (mean half-life 37 hours for females vs. 26 hours for males) (see Table 3). Although these differences result on average in higher area- under-the-curve (AUC) for females compared to males, there is considerable overlap in individual AUCs between groups. Because of substantial individual variation of AUC and half- life, no specific dosage recommendations based on sex are indicated (see DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency:

Liver Disease: In a single-dose study conducted with REMERON(r) 15 mg, the elimination half- life of REMERON(r) was increased 40% in mild to moderately hepatically impaired subjects as compared to patients with normal hepatic function; this effect on elimination resulted in a 57% increase in AUC and a 33% decrease in clearance.

Renal Insufficiency:

Renal Disease: In a single-dose study conducted with REMERON(r) 15 mg, subjects with moderate and severe renal impairment showed a significant decrease in the clearance of ORG 3770 and a consequent increase in the AUC (54% and 215% for moderate and severe renal impairment, respectively). Subjects with severe renal impairment had significantly higher peak plasma levels of ORG 3770 (about double that of subjects without renal impairment). These results suggest that caution must be exercised in administering REMERON(r) to patients who may have compromised renal function.

STORAGE AND STABILITY

Store at controlled room temperature, 15degC - 30degC. Dispense in a tight, light-resistant container.

SPECIAL HANDLING INSTRUCTIONS

The tablets should be swallowed whole with water. The patient should be instructed not to chew the tablet.

DOSAGE FORMS, COMPOSITION AND PACKAGING

REMERON(r) (mirtazapine) Tablets are supplied as: 15 mg Tablets - oval, scored, yellow, coated, with "Organon" embossed on one side and "TZ3" on the other side; available in a carton with 3 blisterpacks; each blisterpack contains 10 tablets. 30 mg Tablets - oval, scored, red-brown, coated, with "Organon" embossed on one side and "TZ5" on the other side; available in a carton with 3 blisterpacks; each blisterpack contains 10 tablets. 45 mg Tablets - oval, white, coated, with "Organon" embossed on one side and "TZ7" on the other side; available in a carton with 3 blisterpacks; each blisterpack contains 10 tablets. Composition: Each film-coated tablet contains 15 mg, 30 mg or 45 mg of REMERON7. Corn starch, hydroxypropyl cellulose, magnesium stearate, colloidal silicon dioxide, lactose monohydrate, hydroxypropylmethyl cellulose, polyethylene glycol 8000, titanium dioxide, yellow iron oxide (15 mg), or yellow and red iron oxides (30 mg) or no colourants (45 mg) are present as non-medicinal ingredients.

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Mirtazapine Chemical name: 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3- c] benzazepine Molecular formula and molecular mass: C17H19N3 and 265.36 Structural formula:

pKa:

pH:

Partition coefficient:

Description:

Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water

CLINICAL TRIALS

Clinical Trials Showing Efficacy

The efficacy of REMERON(r) (mirtazapine) Tablets in the treatment of depression was demonstrated in four U.S. placebo-controlled trials (6 week duration) in adult outpatients meeting DSM III criteria for major depression. Patients were titrated with mirtazapine starting at a dose of 5 mg/day up to a dose of 35 mg/day (by the beginning of Week 3). Outcome measures included the Hamilton Depression Rating Scale (21-item), and the Montgomery and Asberg Depression Rating Scale. The mean mirtazapine dose for patients completing the four studies ranged from 21 to 32 mg/day. Additional supportive studies used higher doses up to 50 mg/day. In the U.S. short-term flexible-dose controlled trials (REMERON(r) Tablets, N = 323), 70% and 54% of the patients received final doses >= 20 mg and >= 25 mg, respectively. In a longer-term study, patients meeting DSM-IV criteria for major depressive disorder who had responded during an initial 8 to 12 weeks of acute treatment on REMERON(r) Tablets were

randomized to continuation of REMERON(r) Tablets or placebo for up to 40 weeks of observation for relapse. Response during the open phase was defined as having achieved a HAMD-17 total score of <= 8 and a CGI-Improvement score of 1 or 2 at two consecutive visits, beginning with Week 6 of the 8 - 12 weeks in the open-label phase of the study. Relapse during the double-blind phase was determined by the individual investigators. Patients receiving continued REMERON(r) treatment experienced significantly lower relapse rates over the subsequent 40 weeks compared to those receiving placebo. This pattern was demonstrated in both male and female patients.

DETAILED PHARMACOLOGY

REMERON(r) (mirtazapine) and its enantiomers have been studied for their pharmacological effects in behavioural models for depression (Table 4) in mice and rats, in EEG-derived rat sleep-waking analysis and in receptor interaction studies [receptors for noradrenaline, serotonin (5-HT), histamine, acetylcholine and dopamine in rats and guinea pigs].

TABLE 4 CNS-PHARMACOLOGICAL PROFILE OF REMERON(r) (MIRTAZAPINE) AND ITS ENANTIOMERS

Pharmacological Indices of Side Effects (Table 4)

The commonly observed side-effects of anti-depressants that can be ascribed to receptor interactions are those of anticholinergic (dry mouth, blurred vision, constipation, urinary retention), a1-adrenolytic (orthostatic hypotension) and antihistaminic (sedation) origin. REMERON(r) (mirtazapine) is virtually devoid of anticholinergic activity, as has been shown in in vitro receptor interactions and confirmed in the in vivo tremorine antagonism test. It is therefore predicted that the incidence of anticholinergic side-effects observed with REMERON(r) in clinical practice should be low. This has been confirmed in clinical trials. REMERON(r) is a moderately weak antagonist at central and peripheral a1 adrenoceptors, as observed in vitro in the labelled prazosin binding assay in rat brain cortex homogenates and in the isolated rat vas deferens assay. On the basis of these observations, a low incidence of orthostatic hypotension would be predicted, which is in line with the clinical observations in depressed patients.

Contribution of REMERON(r) (Mirtazapine) Enantiomers to its Pharmacological Profile (Table 4)

In the acquired immobility test for anti-depressant activity, both REMERON(r) (mirtazapine) and the (S)+enantiomer are inactive, whereas the (R)-enantiomer is active. In the olfactory bulbectomized rat, subchronic treatment with the (S)+enantiomer reverses deficient behaviour, whereas the (R)-enantiomer is inactive. However, the bulbectomy-induced decreases in noradrenaline and MHPG levels are reversed by subchronic treatment with the (R)-enantiomer, but not with the (S)+enantiomer. Both enantiomers are active in the conflict-punishment test (display anti-anxiety activity) and in the sleep-waking EEG test in rats (suppression of REM sleep, an effect shared by many psychotropic drugs). In human pharmaco-EEG profiling in healthy volunteers (16), both enantiomers show a clear-cut "anti-depressant" profile, at similar dose levels (0.5 and 1 mg per subject). The enantiomers of REMERON(r) differ considerably with respect to biochemical activity. The a2-blocking activity of REMERON(r) is virtually confined to the (S)+enantiomer, which is also the more potent 5HT2 antagonist. However, the (R)-enantiomer is the active principle in mirtazapine with regard to 5HT3 antagonistic activity. Both enantiomers contribute to a similar extent to the antihistaminic and (weak) a1-adrenolytic properties of REMERON(r).

Contribution of REMERON(r) Mirtazapine) Main Metabolites to its Pharmacological Profile

Demethyl mirtazapine, the only metabolite found in the rat brain after oral administration of REMERON(r), has anti-anxiety activity in the conflict- punishment test in rats, but is less active in the rat EEG profile for anti-depressant activity than the parent compound. The demethyl metabolite is also less active than the parent compound in in vivo tests for a2-blocking and 5HT2 antagonistic activity. This may be due to poor bioavailability upon systemic administration, since the in vitro tests show that the compound is approximately equally active to REMERON(r) as an a2 and 5HT2 antagonist; important indices for therapeutic anti-depressant activity. With respect to antagonism at the histamine H1 receptor, which is probably related to sedation, the demethyl metabolite appears to be less active than the parent compound. 8-hydroxy mirtazapine, 8-hydroxy demethyl mirtazapine and N(2)-oxide of mirtazapine have not been found to penetrate into the rat brain and are inactive in vivo, with the exception of the N(2)-oxide and the 8-hydroxy metabolite, which display some anti-serotonergic activity. In vitro, these metabolites are much less active than the parent compound at important receptors, like the a2, 5HT2 and histamine H1 receptors. They are, therefore, not considered to be relevant for the pharmacodynamic profile of REMERON(r), with regard to therapeutic activity or side-effects. Glucuronide and sulphonate conjugates are not expected to be pharmacologically active and therefore only a limited number of in vivo and in vitro tests have been performed with these metabolites; they did not show any activity.

Cardiovascular Pharmacology of REMERON(r) (Mirtazapine)

In conscious rabbits, REMERON(r) (mirtazapine), at doses of 0.1 and 1.0 mg/kg i.v., has no effect on blood pressure, heart rate and the autonomic nervous system; at 10 mg/kg i.v., REMERON(r) also has no effect on blood pressure and heart rate but slightly reduces the noradrenaline-induced increase in blood pressure and isoprenaline-induced increase in heart rate. In anesthetized cats, REMERON(r), at doses of 0.1 and 1.0 mg/kg i.v., induces no cardiovascular effects and does not affect the autonomic nervous system; at 10 mg/kg i.v., REMERON(r) induces a decrease in blood pressure and heart rate and reduces the changes in blood pressure induced by vagus stimulation and carotid occlusion.

In anesthetized dogs, REMERON(r), at 0.1 mg/kg i.v., does not induce any hemodynamic changes; at 1.0 mg/kg i.v., REMERON(r) slightly decreases heart rate and myocardial contractility and slightly increases peripheral vascular resistance; at a dose of 10 mg/kg i.v., REMERON(r) induces a slight decrease in heart rate and stroke index, resulting in a slightly decreased cardiac index, a decrease in myocardial contractility and an increase in peripheral vascular resistance, resulting in decreased femoral and common carotid blood flow.

In artificially ventilated, anesthetized dogs, cardiotoxicity has been investigated by infusing REMERON(r) intravenously (30 mg/kg/h) until the animal died from cardiac arrest. If the animal was still alive 5 hours after the start of the infusion, the experiment was stopped. Four out of five dogs died at the end of the 5-hour infusion period and one dog survived the infusion period. The mean extrapolated plasma level of REMERON(r) prior to death in these four dogs was approximately 20 ug/mL; this is approximately 200 times the anticipated clinical peak plasma levels. There was a linear relationship between the severity of the cardiovascular effects (e.g., decrease in blood pressure, decrease in cardiac output and decrease in dP/dt) and the measured plasma level of REMERON(r).

TOXICOLOGY

Acute toxicity

The oral LD50 value for REMERON(r) (mirtazapine) in male Swiss mice was 830 mg/kg (760 - 940 mg/kg) after 24 hours and 810 mg/kg (720 - 1010 mg/kg) after 7 days, and in females, 720 mg/kg (620 - 850 mg/kg) after 24 hours and 7 days. The oral LD50 value for REMERON(r) after 24 hours and 7 days was 490 mg/kg (427 - 534 mg/kg) and 320 mg/kg (240 - 430 mg/kg) in male and female Wistar rats, respectively. In a separate study in rats, the enantiomers of REMERON(r) displayed similar acute toxicity, the LD50 being 222 mg/kg and 208 mg/kg for the (R)- and (S)+enantiomers, respectively. Clinical signs observed in both species, mainly at the highest doses, included motor incoordination, reduced activity, ptosis, twitches, abnormally slow respiration and piloerection; these symptoms reached their peak 2 hours after administration and gradually disappeared during the first day. Gross anatomy revealed no drug-related morphological changes.

Repeated dose toxicity

Oral 13-week toxicity studies were carried out with REMERON(r) (mirtazapine) in rats of both

sexes followed by a 4-week recovery period with daily doses of 10, 40 and 120 mg/kg, and in dogs of both sexes followed by a 7-week recovery period at daily doses of 5, 20, and 80 mg/kg. A second study in dogs was performed at a single dose level of 20 mg/kg/day to investigate possible changes in the prostate seen in the initial study in male dogs. One-year toxicity studies, followed by a five-week recovery period, were carried out in rats and dogs with daily doses of 2.5, 20 and 120 mg/kg and 2.5, 15 and 80 mg/kg, respectively.

Subchronic toxicity

Oral administration of REMERON(r) (mirtazapine) at 10 mg/kg/day to Wistar rats for 13 consecutive weeks induced no untoward effects, whereas REMERON(r) (mirtazapine) at 40 and 120 mg/kg/day induced:

mild hepatic cell hypertrophy not indicative of hepatotoxicity and not accompanied by hepatic functional disturbances or degenerative changes

All these findings were reversible after a 4 week post-dosing period. Oral administration of REMERON(r) to Beagle dogs for 13 consecutive weeks induced: increased liver weights not associated with hepatoxicity at dose levels of 5, 20 and 80 mg/kg/day behavioural changes including incidental vomiting, loose defecation, reduced motor activity and body tremors at 20 and 80 mg/kg/day slight body weight loss in male dogs at 80 mg/kg/day decreased red blood cell parameters (hemoglobin and packed cell volume) at 80 mg/kg/day decreased testicular weight associated with reduced spermatogenesis, decreased epididymal weights and reduced epididymal spermatozoal content in two out of five animals at 80 mg/kg/day A significant decrease in prostatic weights was seen in all drug-treated animals, as well as in a male in the control group kept for recovery. This effect was evaluated in a supplementary study (20 mg/kg/day for 13 consecutive weeks), after which it was concluded that the prostatic weight changes found in the first study most probably were not due to REMERON(r) treatment but related to seasonal variations and age differences (younger males appearing to be more sensitive to changes in prostatic weight than the older animals). There is no evidence from the clinical studies to suggest that REMERON(r) will affect the prostate in man.

Chronic toxicity

Oral administration of REMERON(r) (mirtazapine) for one year to Sprague-Dawley rats (2.5, 20 and 120 mg/kg/day) and Beagle dogs (2.5, 15 and 80 mg/kg/day) did not induce any effects additional to those observed in the subchronic toxicity studies. In the rat study, body weight in low-dose (males and females) and mid-dose (females) groups was generally slightly lower than in control animals; there was a marked decrease in body weight in the high-dose animals. Microscopic examinations revealed that the only drug-related finding was an increased incidence of intracytoplasmic vacuolation in the renal proximal convoluted tubules in the high-dose group of rats after 6 months, and those of the high- and intermediate-dose groups after 12 months. In addition, there was an increased incidence of finely granular brown pigment in the cytoplasm of the tubular epithelial cells in the high-dose rats. The above-mentioned changes were not accompanied by any cytoplasmic or nuclear degenerative changes or by any disturbance in the renal function tests. From the light microscopy, it was suggested that the vacuolations are the result of an increase in the size and numbers of the vacuoles constituting the endocytotic/lysosomal system in the proximal convoluted tubules. This was verified by electron microscopic examination of the kidneys. Vacuolations are known to occur whenever there is an incompatibility between material that enters the lysosomes and the digestive enzymes stored there. Thus, in the chronic toxicity study with REMERON(r) in rats, a transient incompatibility may have taken place due to overloading with the high dose of the test material. As in the subchronic 13-week study, tubular vacuolation and brown pigmentation were reversed during the one-month recovery period. Oral administration of REMERON(r) at 2.5 and 15 mg/kg/day to Beagle dogs for 12 months induced no untoward effects, whereas at 80 mg/kg/day, induced: neurological signs (trembling and convulsions) decline in condition and mild gastro-intestinal disturbances body weight loss mainly during the first half of the dosing period decreases in red blood cell parameters (RBC, Hb, PCV) mild increases in alkaline phosphatase and glutamic-pyruvic transaminase during the first half of the dosing period, together with liver enlargement and hepatic cell hypertrophy, possibly indicative of enzyme induction. These changes were not associated with hepatic morphological changes indicative of hepatotoxicity after six or 12 months increases in the erythroid/myeloid ratios in the bone marrow in males and, to a lesser extent, in females receiving 15 or 80 mg/kg/day after 52 weeks of dosing due to mildly decreased total myeloid elements in males and females and mildly increased erythroid elements in males Reversibility of the drug-related effects was seen after the one-month post-dosing period.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis:

Carcinogenicity studies were conducted with mirtazapine given in the diet at doses of 2, 20, and 200 mg/kg/day to mice and 2, 20, and 60 mg/kg/day to rats. Based on AUC exposure, the highest doses used were approximately 0.7 and 1.2 times the maximum recommended human dose (MRHD) of 45 mg/day in mice and rats, respectively. There was an

increased incidence of hepatocellular adenoma and carcinoma in male mice at the high dose. In rats, there was an increase in hepatocellular adenoma in females at the mid and high doses, and in hepatocellular tumours and thyroid follicular adenoma/cystadenoma and carcinoma in males at the high dose. The data suggest that the above effects could possibly be mediated by non- genotoxic mechanisms, the relevance of which to humans is not known. The doses used in the mouse study may not have been enough to fully characterize the carcinogenic potential of REMERON(r) (mirtazapine) Tablets. Mutagenesis: Mirtazapine was not mutagenic or clastogenic and did not induce general DNA damage as determined in several genotoxicity tests: Ames test, in vitro gene mutation assay in Chinese hamster V 79 cells, in vitro sister chromatid exchange assay in cultured rabbit lymphocytes, in vivo bone marrow micronucleus test in rats, and unscheduled DNA synthesis assay in HeLa cells.

Impairment of Fertility.

: In a fertility study in rats, mirtazapine was given at doses up to 100 mg/kg (1.9 times the MRHD on an AUC basis). Mating and conception were not affected by the drug, but estrous cycling was disrupted at doses that were 1.3 times MRHD based on AUC and pre-implantation losses occurred at 1.9 times MRHD based on AUC

REFERENCES

During treatment with these types of medications, it is important that you and your doctor have good ongoing communication about how you are feeling.

published when REMERON(r) was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a

REMERON(r) has been prescribed to you to relieve your symptoms of depression. Treatment with these types of medications is most safe and effective when you and your doctor have good communication about how you are feeling.

seizures, liver or kidney disease, heart problems, diabetes, low blood pressure, glaucoma (increased intra-ocular pressure), high cholesterol and/or high triglycerides (fats in the blood), difficulties in urinating as a result of an enlarged prostate, psychiatric diseases such as schizophrenia and bipolar disorder (alternating periods of elation/overactivity and depressed mood);

about any medications (prescription or nonprescription) you are taking (refer to the next section for specific interactions with REMERON(r))

if you are pregnant or thinking of becoming pregnant, or if you are breastfeeding;

if you have hereditary galactose intolerance or glucose- galactose malabsorption.

Refrain from potentially hazardous tasks, such as driving a car or operating dangerous machines, until you are certain that this medication does not affect your mental alertness or physical coordination.

concentrating, headache, tremor, nausea, vomiting, sweating or other symptoms may occur after stopping or reducing the dosage of

hydroxypropylmethyl cellulose, lactose monohydrate, magnesium stearate, polyethylene glycol 8000, titanium dioxide, yellow iron oxide (15 mg), or yellow and red iron oxides (30 mg) or no colourants (45 mg)

15 mg Tablets - oval, scored, yellow, coated, with "Organon" embossed on one side and "TZ3" on the other side; available in a

30 mg Tablets - oval, scored, red-brown, coated, with "Organon" embossed on one side and "TZ5" on the other side; available in a carton with 3 blisterpacks; each blisterpack contains 10 tablets.

45 mg Tablets - oval, white, coated, with "Organon" embossed on one side and "TZ7" on the other side; available in a carton with 3 blisterpacks; each blisterpack contains 10 tablets.

your doctor immediately if you have these or any other symptoms. Your doctor may adjust the dosage of REMERON(r) to alleviate these symptoms.

Post-marketing reports indicate that some newborns whose mothers took an SSRI (Selective Serotonin Reuptake Inhibitor) or other newer anti-depressants, such as REMERON(r), during pregnancy

have developed complications at birth requiring prolonged hospitalization, breathing support and tube feeding. Reported symptoms include: feeding and/or breathing difficulties, seizures, tense or overly relaxed muscles, jitteriness and constant crying. In most cases, the newer anti-depressant was taken during the third trimester of pregnancy. These symptoms are consistent with either a direct adverse effect of the anti-depressant on the baby, or possibly a discontinuation syndrome caused by sudden withdrawal from the drug. These symptoms normally resolve over time.

However, if your baby experiences any of these symptoms, contact your doctor as soon as you can.

If you are pregnant and taking an SSRI or other newer anti- depressants, such as REMERON(r), you should discuss the risks and benefits of the various treatment options with your doctor. It is very

important that you do NOT stop taking these medications without first consulting your doctor.

Do not use REMERON(r) if you are taking or have recently taken monoamine oxidase inhibitors (e.g., phenelzine sulphate, moclobemide, tranylcypromine sulphate, or selegeline), thioridazine, or pimozide.

You should tell your doctor if you are taking or have recently taken any medications (prescription, non-prescription or natural/herbal), especially:

other drugs that affect serotonin such as tryptophan, triptans, lithium, tramadol, linezolid, St. John's Wort

drugs used to treat Human Immunodeficiency Virus (HIV), such as a combination of fosamprenavir and ritonavir

benzodiazepines (e.g midazolam, oxazepam and diazepam) - as REMERON(r) may add to the sedative effects of these agents.

doctor has instructed. Generally, most people take between 15 mg and 45 mg per day.

your doctor has instructed. Generally, most people take between 15 mg and 45 mg per day.

you, or those in your care if you are a caregiver or guardian, are taking unless your doctor tells you to, and do not stop taking this medication without consulting your doctor (see Warnings and Precautions when taking

Some symptoms may begin to improve within about two weeks, but significant improvement can take several weeks. Continue to follow the doctor's instructions.

The tablets should be taken at the same time each day, preferably as a single evening dose (prior to sleep). Do not chew them.

The doctor may tell you to take your medicine for several months. Continue to follow the doctor's instructions.

If you forget to take your evening dose, do not take the missed dose the next morning. Continue treatment in the evening (prior to sleep) with your normal dose.

If you have taken a large number of tablets all at once, contact your doctor, the nearest hospital emergency department or the nearest

Poison Control Centre immediately, even though you may not feel sick. Show the doctor your pack of pills.

If you forget to take your evening dose, do not take the missed dose the next morning. Continue treatment in the evening (prior to sleep) with your normal dose.

You may experience some side effects, such as increase in appetite, swollen ankles or feet, occasional dizziness or faintness (especially when you get up quickly from a lying or sitting position), nausea and headache. In rare cases, other effects may include rash, abnormal sensation in the skin (e.g., burning, stinging, tickling or tingly), increased number of white blood cells, involuntary trembling of muscles (tremor), dry mouth, tiredness. In very rare cases, other effects may include abnormal sensations in the mouth, sensations of numbness in the mouth and swelling in the mouth. Some side effects are temporary. Consult your doctor if you experience these or other side effects, as the dose may have to be adjusted.

New or Worsened Emotional or Behavioural Problems Particularly in the first few weeks of treatment, or when doses are adjusted, a small number of patients taking drugs of this type may feel worse instead of better; for example, they may experience unusual feelings of agitation, hostility or anxiety, or have impulsive or disturbing thoughts such as thoughts of self-harm or harm to others. Should this happen to you, or to those in your care if you are a caregiver or guardian, consult your doctor immediately; do not discontinue your medication on your own.

Stop taking the drug and contact your doctor immediately if you experience an allergic reaction or any severe or unusual side effects.

This is not a complete list of side effects. For any unexpected effects while taking REMERON(r), contact your doctor or pharmacist.

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected side effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance:

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Organon Canada Ltd at: 1-800-463-5442

This leaflet was prepared by Organon Canada Ltd. Last revised: September 26, 2008.

Route of Administration	Dosage Form/Strength	Clinically Relevant Nonmedicinal Ingredients
oral	Tablets, 15, 30 and 45 mg	lactose For a complete listing, see Dosage Forms, Composition and Packaging section.

Group	T 1/2 (MEAN +- SD) *
Group	Single Dose	Multiple Dose
Adult male N=9	21.7 +- 4.2	22.1 +- 3.7
Adult female N=9	37.7 +- 13.3	35.4 +- 13.7
Elderly # male N=8	32.2 +- 15.4	31.1 +- 15.1
Elderly # female N=8	40.6 +- 12.8	39.0 +- 10.8

CNS-Pharmacological Profile	REMERON (r)	(S)+enant.	(R)-enant.
Behavioural models Anti-depressant-like effects bulbectomized rat: behavioural biochemical acquired immobility test Anti-anxiety effects anxiosoif test	+ + - +-	+ - - +-	- + + +-
EEG studies	+ +	+ +	+- +
Anti-depressant profile
sleep (rat) sleep (human)
Receptor interactions	+ + +	+ + +	- - -
Noradrenaline (a 2 -blockade) enhancement NA release rauwolscine displacement antagonism clonidine mydriasis	+ + +	+ + +	- - -
Serotonin affinity 5HT 2 affinity 5HT 3	+ +	+ -	+- +
Histamine - H 1 -antagonism	+	+	+
Acetylcholine QNB binding guinea pig ileum	- -	- -	- -

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom/effect		Talk with your doctor or pharmacist		Stop taking drug and call your
Symptom/effect		Only if severe	In all cases	Stop taking drug and call your
	Symptoms of depression (anxiety and disturbed sleep)	[?]
	New or worsened emotional or behavioural problems		[?] *
Very Rare	A combination of symptoms such as unexplainable fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes and unconsciousness (can be signs of serotonin syndrome)		[?] *
SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom/effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmaci st
Symptom/effect		Only if severe	In all cases	Stop taking drug and call your doctor or pharmaci st
Common	Drowsiness which can lead to impaired concentration, generally occurring during the first few weeks of treatment	[?]
Common	Weight gain	[?]
Rare	Bruising and/or unusual bleeding and symptoms of infection such as sudden high fever, sore throat, mouth ulcers, severe digestive system disturbances or other signs of infection (symptoms of blood cell disturbances).		[?] *
	Convulsions (loss of consciousness with uncontrollable shaking)			[?] *
	Fainting/loss of consciousness		[?]
	Nightmares/vivid dreams , agitation or confusion		[?]
	Hallucinations (strange visions or sounds)		[?]
	Mania (feeling elated or emotionally 'high' )		[?] *
	Feeling restless and unable to stand still	[?]
	Uncontrolled, sudden movements	[?]
	Restless legs (feeling of unrest during night mainly located in the legs combined with sudden muscle contractions in the legs)	[?]
	Pain in the joints or muscles		[?]
	Jaudice (yellowing of eyes or skin, dark urine		[?] *

Date of Revision: September 26, 2008

Submission Control No: 123061

PART I: HEALTH PROFESSIONAL INFORMATION 3

PART II: SCIENTIFIC INFORMATION 24

PART III: CONSUMER INFORMATION. 34

REMERON(r)

PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION

INDICATIONS AND CLINICAL USE

Adults

Long-term use of REMERON(r)

Geriatrics (> 65 years of age):

Pediatrics (< 18 years of age):

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM

Pediatrics: Placebo-Controlled Clinical Trial Data

The small denominators in the clinical trial database, as well as the variability in placebo rates, preclude reliable conclusions on the relative safety profiles among these drugs.

Adults and Pediatrics: Additional Data

Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages. This includes monitoring for agitation- type emotional and behavioural changes.

Discontinuation Symptoms

Lactose

Agranulocytosis

Discontinuation of Treatment with REMERON(r)

Diabetes

Hepatic Impairment

Jaundice:

Renal and Hepatic Impairment

Pediatrics (< 18 years of age):

Geriatrics (> 65 years of age)

ADVERSE REACTIONS

Adverse Events Leading to Discontinuation of Treatment

Adverse Events Occurring at an Incidence of 1% or More Among REMERON(r)-Treated Patients:

TABLE 1 INCIDENCE OF ADVERSE CLINICAL EXPERIENCES (>=1% for REMERON(r)) IN U.S. SHORT-TERM PLACEBO-CONTROLLED STUDIES1,2,3

Body as a Whole: frequent: infrequent: rare:

Cardiovascular System: frequent: infrequent: rare:

Digestive System: frequent: infrequent: rare:

Endocrine System: rare:

Hemic and Lymphatic Systems: rare:

Metabolic and Nutritional Disorders: frequent: infrequent: rare:

Musculoskeletal System: frequent: infrequent: rare:

Nervous System: frequent: infrequent: rare:

Respiratory Systems: frequent: infrequent: rare:

Skin and Appendages: frequent: infrequent: rare:

Special Senses: infrequent: rare:

Urogenital System: frequent: infrequent: rare:

Abnormal Laboratory Values:

Adverse Events Observed During Post-Marketing Evaluation of REMERON(r)

Table 2. Post-marketing reported adverse events with REMERON(r)

DRUG INTERACTIONS

Serious Drug Interactions

Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS

CYP Enzyme Inducers

CYP3A4 Inducers (these studies used both drugs at steady state):

Phenytoin:

Carbamazepine:

CYP Enzyme Inhibitors

Cimetidine:

Ketoconazole:

Other Drug-Drug Interactions

Amitriptyline

Warfarin:

Lithium:

DOSAGE AND ADMINISTRATION

REMERON(r) (mirtazapine) is not indicated for use in children under 18 years of age (see WARNINGS AND PRECAUTIONS: POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM)

TREATMENT OF PREGNANT WOMEN DURING THE THIRD TRIMESTER:

Children:

See WARNINGS AND PRECAUTIONS: POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM

ELDERLY AND PATIENTS WITH MODERATE TO SEVERE RENAL OR HEPATIC

ADULTS:

Administration of REMERON(r) (Mirtazapine) Tablets

OVERDOSAGE

Overdose Management:

ACTION AND CLINICAL PHARMACOLOGY

TABLE 3 EFFECT OF AGE AND GENDER ON PLASMA HALF-LIFE OF MIRTAZAPINE

Geriatrics:

Gender:

Age and Sex:

Hepatic Insufficiency:

Renal Insufficiency:

STORAGE AND STABILITY